Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00130702 · ClinicalTrials.gov registry record · Phase 2
Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT00130702 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 18 participants.
The verdict
NCT00130702, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to determine how effective, and to what extent, Iressa is in the treatment of acute myelogenous leukemia.
Interventions
- DRUG gefitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2005-08 |
| Est. Completion | 2007-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00130702
The ClinicalTrials.gov registry entry for NCT00130702 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which gefitinib is the first listed.
NCT00130702 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00130702 about?
NCT00130702 is a clinical study titled "Study of Iressa in Patients With Relapsed or Refractory Acute Myelogenous Leukemia". The purpose of this study is to determine how effective, and to what extent, Iressa is in the treatment of acute myelogenous leukemia.
What is the current status of trial NCT00130702?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2005-08. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00130702?
The interventions under investigation include: gefitinib (DRUG).
Who is sponsoring clinical trial NCT00130702?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.